Market research
EVE.AU EVE Investments Limited
AU AUD Consumer Defensive
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 5M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.47
Profile
Company facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Consumer Defensive
- Industry
- Packaged Foods
- ISIN
- AU000000EVE3
- Market cap
- 5M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.47
About
About EVE Investments Limited
EVE Health Group Limited, together with its subsidiaries, engages in the development, retail, and commercialization of health and wellness, and pharmaceutical products. The company lead product is Dyspro, a proprietary pharmaceutical-grade formulation to address dysmenorrhea (menstrual pain); and Libbo, a proprietary pharmaceutical-grade oral dissolving film formulation for the treatment of erectile dysfunction. It also offers Lactobacillus rhamnosus Beebiotic MAP01, a proprietary strain to support digestive health and vitality. The company was formerly known as EVE Investments Limited. EVE Health Group Limited was incorporated in 2003 and is based in Subiaco, Australia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the EVE.AU discussion.
5 years, 4 months ago
EVE Investments Limited is currently in a long term downtrend where the price is trading 48.3% below its 200 day moving average.
From a valuation standpoint, the stock is 88.7% cheaper than other stocks from the Financial Services sector with a price to sales ratio of 6.0.
EVE Investments Limited's total revenue rose by 164.9% to $2M since the same quarter in the previous year.
Its net income has increased by 19.3% to $-1M since the same quarter in the previous year.
Finally, its free cash flow grew by 45.9% to $-379K since the same quarter in the previous year.
Based on the above factors, EVE Investments Limited gets an overall score of 4/5.